

Solos Endoscopy, Inc. Completes Capital Restructuring

WESTPORT, CT, November 27, 2020 Solos Endoscopy, Inc. (OTCPK: SNDY today announced that that the Company has amended its Certificate of Incorporation to authorize and effectuate a one-for-two hundred and fifty (1-for-250) reverse stock split of its Common shares, par value \$0.001 per share . The Company's common shares are expected to begin trading on a split-adjusted basis when the market opens on December 01, 2020 under the new symbol "SNDYD" and under the following new CUSIP number 23256Q105.

The Board of Directors and the majority stockholder duly authorized and approved the capital restructure as a means to position the Company to be more attractive for potential investors and to better reflect the Company's value as compared to other companies in the medical device market.

As a result of the reverse stock split, the authorized number of common shares has been reduced from 2,900,000,000 to 250,000,000, par value \$0.0001 per share. In addition, the Company's issued and outstanding common shares has been reduced from 1,247,087,723 shares to approximately 5,000,000 shares. All outstanding rights to purchase the Company's Common shares are adjusted proportionately as a result of the reverse stock split.

The Company will not issue fractional shares of its Common shares in the reverse stock split. Instead, all fractional shares have been "rounded up to the nearest whole number" and each holder of fewer than 250 shares will receive 1 share.

The company's transfer agent, Pacific Stock Transfer Company ("Pacific Stock"), is acting as the exchange agent for the reverse stock split. Pacific Stock will provide instructions to shareholders of record regarding the exchange of stock certificates. Shareholders who hold their shares in brokerage accounts or "street name" are not required to take any action to affect the exchange of their shares.

About Solos Endoscopy, Inc.: Solos Endoscopy Inc. has long provided quality healthcare instruments to hospitals across the United States. For more than 30 years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.Solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise, as well as the company's inability to raise additional capital, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcm Markets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9700